Travere Therapeutics (TVTX) Tax Provisions (2014 - 2026)
Travere Therapeutics (TVTX) posted Tax Provisions of -$120000.0 for Q1 2026, down 113.03% on a QoQ basis from $921000.0 in Q4 2025, and down 407.69% year-over-year from $39000.0 in Q1 2025.
Travere Therapeutics (TVTX) Tax Provisions (2014 - 2026) Analysis & Trends
Travere Therapeutics' Tax Provisions history runs 13 years deep, the most recent figure standing at -$120000.0 for Q1 2026.
- Quarterly Tax Provisions fell 407.69% year-over-year to -$120000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $829000.0 (up 2690.62% YoY) and the FY2025 annual result came in at $988000.0, up 723.33% from the prior year.
- Tax Provisions was -$120000.0 for Q1 2026 at Travere Therapeutics, down from $921000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $921000.0 in Q4 2025 and bottomed at -$120000.0 in Q1 2026.
- A 5-year average of $89647.1 and a median of $53000.0 in 2022 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2022 — Tax Provisions jumped 1475.0% — and 2024, when it tumbled 800.0%.
- Travere Therapeutics' Tax Provisions stood at $63000.0 in 2022, then advanced by 7.94% to $68000.0 in 2023, then tumbled by 205.88% to -$72000.0 in 2024, then surged by 1379.17% to $921000.0 in 2025, then plunged by 113.03% to -$120000.0 in 2026.
- Business Quant data shows TVTX's Tax Provisions at -$120000.0 in Q1 2026, $921000.0 in Q4 2025, and $8000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 125,146.46 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -859,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 31.86 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 221.50 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -60.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Travere Therapeutics | 5.25 Bn | 5.25 Bn | 125.25 Mn | -120,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -120,000.00 |
| Dec 31, 2025 | 921,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Mar 31, 2025 | 39,000.00 |
| Dec 31, 2024 | -72,000.00 |
| Sep 30, 2024 | -84,000.00 |
| Jun 30, 2024 | 85,000.00 |
| Mar 31, 2024 | 191,000.00 |
| Dec 31, 2023 | 68,000.00 |
| Sep 30, 2023 | 12,000.00 |
| Jun 30, 2023 | 65,000.00 |
| Mar 31, 2023 | 78,000.00 |
| Dec 31, 2022 | 63,000.00 |
| Sep 30, 2022 | 145,000.00 |
| Jun 30, 2022 | 53,000.00 |
| Mar 31, 2022 | 52,000.00 |
| Dec 31, 2021 | 4,000.00 |
| Sep 30, 2021 | 43,000.00 |
| Jun 30, 2021 | 49,000.00 |